1. 174-US, 2008. Protocol 3151A1-174-US: An open-label, randomized, single-dose, dose-proportionality study of desvenlafaxine SR in healthy subjects. From: FDA Approval Package (NDA: 21-992) – Clinical Pharmacology and Biopharmaceutics Review Part 4, pp. 227–239. (accessed 11.11.14).
2. 181-US, 2008. Protocol 3151A1-181-US: an open-label, randomized, single-dose, 4-period crossover study to determine the effect of a low-fat, medium-fat, and high fat meal in relationship to fasting on the relative bioavailability, pharmacokinetic profile, safety and tolerability of DVS-233 SR in healthy adults. From: FDA Approval Package (NDA: 21-992) – Clinical Pharmacology and Biopharmaceutics Review Parts 5 and 6, pp. 315–372. (accessed 11.11.14).
3. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res.,1995
4. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments;Artursson;Pharm. Res.,1993
5. PAMPA-a drug absorption in vitro model: 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates;Avdeef;Eur. J. Pharm. Sci.,2004